The functional activity loss of the PBRM1 mutation has been clinically validated to potentially enhance the efficacy of targeted therapy.[2, 34, 35] To investigate the hypothesis that PBRM1 knockdown may impact immunotherapy sensitivity in ccRCC, we administered anti‐PD‐1 mAb to BALB/c mice with Renca cells expressing either wild‐type or knockdown Pbrm1. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.